Interestingly, we demonstrated that rHGFK1 treatment also reduced the frequency of CDDP-enriched CD90+ CSCs and Wnt/β-catenin signaling, suggesting that rHGFK1 may be a potential antagonist of Wnt signals in HCC. Here, THY1 is linked to hepatocellular carcinoma.